Lineage Cell Therapeutics, Inc., a prominent biotechnology company operating within the health care sector, has been making significant strides in the field of cell-based therapies and gene marker-based molecular diagnostics. The company, headquartered in Carlsbad, United States, is listed on the NYSE American and trades under the currency of USD. As of September 7, 2026, the close price of Lineage Cell Therapeutics’ stock was recorded at $1.09. This figure represents a notable fluctuation from its 52-week high of $2.09, achieved on November 2, 2025, to a 52-week low of $1 on July 26, 2026.
The company’s market capitalization stands at approximately $273.14 million, reflecting its current valuation in the biotechnology industry. Despite its innovative contributions to cell-based therapies and molecular diagnostics, Lineage Cell Therapeutics has reported a price-earnings ratio of -6.601, indicating challenges in achieving profitability.
Lineage Cell Therapeutics, Inc. is dedicated to developing advanced therapeutic solutions aimed at treating a variety of diseases and degenerative conditions. The company’s focus on cell-based therapies involves leveraging the body’s own cells to repair and regenerate damaged tissues, offering potential breakthroughs in medical treatments. Additionally, its gene marker-based molecular diagnostics are designed to enhance the precision of disease detection and monitoring, thereby improving patient outcomes.
Operating nationwide, Lineage Cell Therapeutics continues to expand its research and development efforts, striving to bring innovative treatments to market. The company’s commitment to advancing biotechnology underscores its role as a key player in the health care sector, despite the financial challenges reflected in its current stock performance and earnings metrics.
